Small molecule screen identifies pyrimethamine as an inhibitor of NRF2-driven esophageal hyperplasia

Authors

Chorlada Paiboonrungruang, North Carolina Central University
Brittany Bowman, Washington University School of Medicine in St. Louis
Julius Chembo, Washington University School of Medicine in St. Louis
M Ben Major, Washington University School of Medicine in St. Louis
et al.

Journal

Redox Biology

Publication Date

11-1-2023

Volume

67

First Page

102901

Document Type

Open Access Publication

DOI

10.1016/j.redox.2023.102901

Rights and Permissions

Paiboonrungruang C, Xiong Z, Lamson D, Li Y, Bowman B, Chembo J, Huang C, Li J, Livingston EW, Frank JE, Chen V, Li Y, Weissman B, Yuan H, Williams KP, Ben Major M, Chen X. Small molecule screen identifies pyrimethamine as an inhibitor of NRF2-driven esophageal hyperplasia. Redox Biol. 2023 Nov;67:102901. doi: 10.1016/j.redox.2023.102901. © 2023 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/bync-nd/4.0/).

Recommended Citation

Paiboonrungruang, Chorlada; Bowman, Brittany; Chembo, Julius; Ben Major, M; and et al., "Small molecule screen identifies pyrimethamine as an inhibitor of NRF2-driven esophageal hyperplasia." Redox Biology. 67, 102901 (2023).
https://digitalcommons.wustl.edu/oa_4/2870

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.